



Walter P. Drake, JD, PhD
Curriculum Vitae 2019

Research Scientist and Attorney
Citizenship: USA

Name: Walter Peter Drake

Address/Phone 1410 Parkview Circle #101
Wilmington, NC 28405

Mobile Phone: 910-228-0070

Email: wpdrake@hotmail.com

Education:

Bachelor Degree (B.A.), Johns Hopkins University (Baltimore, Maryland) 1968

Masters Degree (M.A.), Molecular Biology, Johns Hopkins University 1971**

Doctor of Law (J.D.), University of Baltimore School of Law 1975

Doctor of Philosophy (Ph.D.), Stem Cell Biology, Panama College of Cell Science 2013

**Education Note: Completed all course requirements for PhD degree within the Dept. of Biology, Johns Hopkins University, including passing Comprehensive Examination. However, after 1 year of laboratory research in microbiology toward a dissertation, left the program with a Masters Degree, in order to begin research at the National Cancer Institute

Law License: State of Maryland

CAREER SUMMARY

(A) Scientific Career: For the 5 years 1971-1975, I was employed by the Baltimore Cancer Research Center, a division of the United States National Cancer Institute in position of Research Chemist. I conducted scientific experiments in the fields of immunology and cancer biology, and am principle author of 29 biomedical research reports published in scientific journals. While engaged in this work, I had supervisory control over up to 4 other scientists and interns, and I reported directly to the Chief, Section of Immunology and Cell Biology. A **Bibliography** of my publications is attached.

My first report, **Drake WP et al “Preservation of Cellular Antigenicity in Tumor Cells By the Use of Formalin Fixation”, Cancer Research 32:1042-1044 (1972)**, showed that formalin treated tumor cells could elicit a strong immune response measured by the development of antibody to the cells when injected into a mouse. Over the years, this study has been cited many times by other scientists. In 2003, this report was cited as the basis to make a patient vaccine by treating a patient’s tumor cells with formalin and injecting into the patient with beneficial results. **Pizza G, et al, “Allogeneic Gene-Modified Tumour Cells in Metastatic Kidney Cancer: Preliminary Report”, Folio Biological (Praha) 49:147-159 (2003)**.

Other highlights include the selection as former Peer Review Scientist for the Journals: Journal of Histology and Cell Biology; Biomedicine.

(B) Legal Career (State of Maryland, USA, 1976-2001): In 1976, having obtained a law degree from an evening program while working as a scientist, I began my law career. I trained on and eventually handled medical malpractice and severe injury trials; and also represented companies involved in medical matters such as Immunodiagnostics and Immunotherapeutics Inc., a company engaged in allergy control and clinical research; 1985-1990 Attorney for Clinica Corporation, a development stage company founded to develop cancer screening tests. In 1988, I successfully filed a Prospectus with the United States Securities and Exchange Commission (SEC) to register Maridel Motors Inc. for an initial public stock offering (IPO). **Current working knowledge of federal and state securities regulations.**

(C) Academic Research and Educational Activities (2001-Present):

Founder, Drake Biomedical Institute, 2001

After coming to Phuket, Thailand on a sabbatical of unspecified duration, I saw a report of the curing of blindness in a Thai patient by the use of stem cells. This was a new area of medicine that excited me, and shortly thereafter I founded the Drake Biomedical Institute, a private research institute, to engage in research and education relating to stem cell treatments available internationally.. Organized in the USA, the Institute engaged in core educational services, with the current interest being the formulation of transdermal preparations of herbal biologicals for use in therapy.



Walter P. Drake, Thailand Circa 2005

Founder, Panama College of Cell Science, 2005

The Panama College of Cell Science was organized in 2005 to train clinicians, and other students interested in the biological sciences, concerning the new advances being developed worldwide for adult stem cell treatments. Previous to 2005, there were no training programs in adult stem cells nor any interest in the research community in adult stem cells, almost 99% of research efforts concentrated on Embryonic Stem Cells at that time. Because it was clear that Embryonic Stem Cells could never be used in therapy and to satisfy a void in training in Adult Stem Cell therapies (primarily those stem cells collected from patients themselves), the Panama College of Cell Science was established to train students in this “New Medicine”. In connection with the Panama College of Cell Science, I currently serve as Director and part-time Instructor, and played a major role in the curriculum design and selection of instructional technology for the program. In 2017, along with other talented colleagues, I was co-author of the first safety analysis research report published in the United States: Comella, K et al, “Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction”. **J Clin Med Res 2017: 9(11): 935-942.**

Special Instructor, Blue Marble University Medical School, 2010-Present

Part-time Instructor in Autologous Stem Cell Therapy, Medical Devices, Hospital Management, Research-Basic and Clinical, and Pharmacology, for Blue Marble University Medical School, an online medical school offering an Executive type M.D. degree for non-clinical careers.

Biomedical Publications

1. Drake WP, Ungaro PC, and Mardiney MR Jr.: Preservation of Cellular Antigenicity of Tumor Cells by the Use of Formalin Fixation. **Cancer Research 32:1042-1044, 1972.**

2. Markham RV, Sutherland TC, Cimino EF, Drake WP, and Mardiney MR Jr.: Immune Complexes Localized in the Renal Glomeruli of AKR Mice: The Presence of MuLV gs-1 and C-Type RNA Tumor Virus gs-3 Determinants. **European Journal of Clinical and Biological Research 17(7):11-15, 1972.**

3. Ungaro PC, Drake WP, Buchholz DH, and Mardiney MR Jr: Alteration of Specificity of AntiTumor Antisera by the Use of Passively Administered Antibody. **Cancer Research 32:1521-1525, 1972.**

4. Drake WP, Ungaro PC, and Mardiney MR Jr: Formalin-Fixed Cell Preparations for Use in the Automated Trypan Blue Cytotoxic Assay. **Transplantation 14:127-130, 1972.**
5. Ungaro PC, Drake WP, and Mardiney MR Jr: The Formalinization of Antibody to Tumor Cells in Altering the Immune Response. **Cancer Research 32:2241-2247, 1972.**
6. Drake WP, Ungaro PC, and Mardiney MR Jr: The Measurement and Manipulation of Hemolytic Complement Levels in Tumor Bearing C57BL/6 Mice. **Biomedicine 18:284-289, 1973.**
7. Ungaro PC, Drake WP, and Mardiney MR Jr: Augmentation of Antitumor Antibody Activity by the Use of Lyophilization. **Journal of the National Cancer Institute 50:201-204, 1973.**
8. Ungaro PC, Drake WP, and Mardiney MR Jr: Repetitive Administration of Bacillus Calmette Guerin in the Treatment of Spontaneous Leukemia of AKR Mice. **Journal of the National Cancer Institute 50:125-128, 1973.**
9. Drake WP, Ungaro PC, and Mardiney MR Jr: The Passive Administration of Antiserum and Complement in Producing Anti-E14 Cytotoxic Activity in the Serum of C57BL/6 Mice. **Journal of the National Cancer Institute 50:909-914, 1973.**
10. Drake WP, and Mardiney MR Jr: The Enhancement of Antitumor Antibody Binding to Cross-Reactive Normal Tissue Antigens. **Transplantation 16:189-198, 1973.**
11. Drake WP, LeGendre SM, and Mardiney MR Jr: Depression of Complement Activity in Three Strains of Mice After Tumor Transfer. **International Journal of Cancer 11:719-724, 1973.**
12. Mardiney MR Jr, Ungaro PC, and Drake WP: Immunoprophylaxis and the Treatment of Leukemia in AKR Mice: Repetitive Use of BCG. **National Cancer Institute Monograph, 39:89-90, 1973.**
13. Drake WP, Cimino EF, Mardiney MR Jr, and Sutherland JC: Prophylactic Therapy of Spontaneous Leukemia of AKR Mice with Polyadenylic acid-Polyuridylic acid (Poly A:U). **Journal of the National Cancer Institute 50:941-944, 1974.**

14. Drake WP, and Mardiney MR Jr: Parameters of Serum Complement in Relation to Tumor Therapy. **Biomedicine 21:206-209, 1974.**

15. Drake WP, Pokorney DR, and Mardiney MR Jr: In Vivo Abrogation of C3 and C5 by Administration of Cobra Venom Factor and Heterologous Anti-C3. **Journal of Immunological Methods 6: 61-72, 1974.**

16. Drake WP, and Mardiney MR Jr: Complement Mediated Alteration of Antibody Specificity in vivo. **J. Immunol. 114: 1052-1057, 1975.**

17. Drake WP, Roberts GC, Pendergrast WJ, and Mardiney MR Jr: The Kinetics of the Interaction of Heterologous Anti-Tumor Serum and Heterologous Complement in Non-Tumor Bearing Mice. **Biomedicine 22(6): 502-508, 1975.**

18. Drake WP, Pokorney DR, Chipman S, Levy CC, and Mardiney MR Jr: Elevated Ribonuclease Activity in the Thymus and White Blood Cells of Genetically Cancer Prone Mice. **J. Experimental Med. 141: 918-923, 1975.**

19. Drake WP, Kopyta LP, Levy CC, and Mardiney MR Jr: Alterations in Ribonuclease Activities in the Plasma, Spleen, and Thymus of Tumor-Bearing Mice. **Cancer Research 35: 322-324, 1975.**

20. Drake WP, Pokorney DR, Ruckdeschel JC, Levy CC, and Mardiney MR Jr: A White Blood Cell Ribonuclease Assay for the Possible Monitoring of Malignancy. **J. Natl. Cancer Institute 54(6): 1475-1478, 1975.**

21. Drake WP, Schmuckler M, Pendergrast WJ, Davis AS, Lichtenfeld JL, and Mardiney MR Jr: Abnormal Profile of Human Nucleolytic Activity as a Diagnostic Test For Cancer. **J. Natl. Cancer Institute 55:1055, 1975.**

22. Pendergrast WJ, Drake WP, and Mardiney MR Jr: The Dependence of Successful Immunotherapy on Adequate Tumor Burden. **J Natl. Cancer Institute 55: 1223-1225, 1975.**

23. Drake WP, Pendergrast WJ Jr., Kramer RE, and Mardiney MR Jr.: Enhancement of Spontaneous C3H/HeJ Mammary Tumorigenesis by Long-Term Polyadenylic-Polyuridylic Acid Therapy. **Cancer Res. 35(11): 3051-3, 1975.**

24. Drake WP, Pokorney DR, Kopyta LP, and Mardiney MR Jr.: In Vivo Decomplementation of Guinea Pigs with Cobra Venom Factor and Anti-C3 Serum: Analysis of the Requirement of C3 and C5 for Mediation of Endotoxin-Induced Death. **Biomedicine Express 25(3): 91-94, 1976.**

25. Drake WP, Pendergrast WJ Jr., Kramer RE, and Mardiney MR Jr.: The Age-Dependant Efficacy of Polyadenylic-Polyuridylic Acid Therapy Upon the Development of Spontaneous Leukemia in AKR Mice. **Cancer Res. 36(3): 1172-5, 1976.**

26. Pendergrast WJ Jr., Drake WP, and Mardiney MR Jr.: A Proper Sequence for the Treatment of B16 Melanoma: Chemotherapy, Surgery, and Immunotherapy. *J. Natl. Cancer Inst.* 57(3): 539-44, 1976.

27. Drake WP, Roberts GC, and Mardiney MR Jr.: Latent Homology of Murine Lymphoid Antigens Revealed Through the Complement Mediated Absorption of Xenogenic Antiserum. **Biomedicine 24(5): 329-33, 1976.**

28. Ruckdeschel JC, Doukas JG, Drake WP, and Mardiney MR Jr.: Application of Laser Cytometry to the Analysis of Immunologically Induced In Vitro Lymphocyte Responsiveness. **Transplantation 23(5): 396-403, 1977.**

29. Drake WP, Frazier LM, Sidle D, and Mardiney, MR Jr.: Alteration of Cellular Ribonuclease Associated With Murine Oncogenic Virus Infection. **Biomedicine 28: 24-28, 1978.**

30. Drake WP: Use of Formalin to Create Cellular Environments for Stem Cell Differentiation. **Letter to Michael R. Mardiney Jr. MD, September 23, 2007.** Published online by Drake Biomedical Institute (DrakeBiomedicalInstitute.wordpress.com) at: <https://drakebiomedicalinstitute.wordpress.com/about/walter-p-drake/>

31. Comella K., Parlo M, Daly R, Depasquale V, Edgerton E, Mallory P, Schmidt R, Drake WP: Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction. **J Clin Med Res 2017: 9(11): 935-942** [doi: <https://doi.org/10.14740/jocmr3187w%5D>] Full Text: <http://www.jocmr.org/index.php/JOCMR/article/view/3187/1954>

